Dr. Xiaoping Xiao demonstrates outstanding scientific merit in biotechnology through his influential research on host–pathogen interactions, vector biology, and molecular mechanisms of infectious diseases, making him highly suitable for the Scientific Excellence in Biotechnology Award. With 858 citations, 25 publications, and an h-index of 13 in his Scopus profile, his work has achieved significant global impact, particularly in elucidating how insects such as mosquitoes regulate immune defense, microbiome balance, and viral susceptibility. His pioneering studies published in top-tier journals, including Nature Microbiology, Nature Metabolism, Life Medicine, Trends in Parasitology, and PLoS Pathogens, have uncovered key pathways such as the Mesh–Duox regulatory axis, neuron-specific antiviral responses, and C-type lectin-mediated microbiome homeostasis, contributing to fundamental advances in vector immunology and infectious disease control. Dr. Xiao’s research has also bridged biotechnology and translational medicine by identifying metabolic and molecular determinants that influence viral entry and disease progression, including novel insights linking glucose-like metabolites to SARS-CoV-2 inhibition. His innovative contributions extend to biotechnology applications demonstrated by multiple authorized patents related to antiviral proteins, bacteriophage technologies, insect-derived immune molecules, and antimicrobial peptide production. Supported by competitive national and provincial research grants, his investigations continue to advance antiviral strategies, innate immune regulation, and vector-pathogen dynamics. Collectively, his high-impact publications, citation strength, translational innovations, and sustained research leadership strongly affirm his suitability for the Scientific Excellence in Biotechnology Award.